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Abstract Angiogenesis is now recognized to play a pivo阻1role in tumor 
development， and even in the process of carcinogenesis. Trientine dihydrochloride 
(trientine) isused in clinica1 practice as a copper (Cu)-chelating agent. In也iss加dy，we 
elucidate that the effect of仕ientineon加mordevelopment and carcinogenesis is due to 
the suppression of angiogenesis in the murine hepatocellular carcinoma cel (HCC) 
xenograft model and in the rat hepatocarcinogenesis model， respectively. Trientine 
suppressed the tumor development associated with suppression of in仕a-tumoral
angiogenesis. Trientir泥 仕ea旬lentalso resulted in a marked increase of apoptosis in the 
tumor， althougJh tumor cel proliferation itself was not altered. 1n vitro studies also 
showed出attrientine is not cytotoxic for the tumor cells， but it significantly suppressed 
the endothelial cel prol証eration.1n a diethylni仕osarnine (DEN)-induced rat 
hepatocarcinogenesis model，住ientinetrea回 entsigni五cantlysuppressed glulathione 
S-transferase placental form (GST-P)-positive preneoplastic lesions. Trientine also 
markedly suppressed neovascularization in the liver to a similar level 郡山atof 
development of preneoplastic lesions. On the con仕ary，the intrahepatic cel proliferation 
was not altered with or without trientine treaむnent.These results suggested出atCu 
plays a pivotal role泊 HCCtumor development and carcinogenesis via angiogenesis 
suppression. Since trientine is already used in clinical practice without any serious side 
e旺'ects，it may be an e百ectivenew strategy for future HCC therapy. 







































































刺激作用を1rすると共に， vascular endothelial growth 

































エンチンを用いた.ペニシラミンは SigrnaChernica1 Co. 
(St. Lo山s，MO，USA)より購入し，トリエンチンはツム
ラ(東京)より提供を受けた.マウス肝癌細胞として，







ストレプトマイシンを含む DMEM培養液に， 37"C， 

























/EC adhesion molecule (PECAM: CD31)の免疫染色を
おこなった免疫染色は，まず切片に 1次抗体(Phann-
ingen， san Diego， CA; 1:100 dilution)を37"Cで60分間
反応させた後， 2次抗体 (anti"'1'atIgG) (Novoscastra; 

























bromide ) assay法を用いて， in vitroにおける細胞増荊




"C， 5%C02の条件下で24時悶， 48時間， 72時間， 96 
時間培養した後に MTTを0.5mg/m1の濃度で添加し，
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肝内銅波度は， coupled plasma emission spectroscopy 









肝よりmRNAを抽出した後に ABIPrism 7，700 Se-
quence Detection System (PE Applied Biosystems， 


















一・-Pe瓜cil且mine+ norma1 diet 



















Fig. 1. The effect of Copper(Cu)-chelators; penicillaminc and仕ientineon BNL-HCC tumor development. Peni-
cil紅 nine組 dtrientine were administered at a dose of 3，000 ppm in the drinking water at three days af-
terれlfiorimplantation with or without Cu-deficient diet. The tumor volume was determined by 
伺 lipersat the indi回 ted肱nepoints. Each point represents the m回 n土 SD(n=8).* p<0.05， * * p<O.Ol 
compared with the con仕01group. 
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Fig. 2. The dose-ranging study of trientine on加mor
dcveJopment. Trientine was administered at 
dose of 3，000， 1，500， and 750 ppm in the drink-
ing water at 廿lree days after tumor 
implan凶 ion.The tumor volume was deter-
mined by calipers at the indicated time points. 
Each point represcnts the mean士SD(n=8).* 
























Fig. 3. E任'ectof trientine on the plateletAC adbesion 
molecu}e(PECAM/CD31) expression in BNL-
HCC tumors. Untrcated BNL-HCC如mors(A)
叩 dtumors from animals receiving 750 ppm 
trientine(B)釦.eshown. Tumor vascularization 
visualized by immunostaining of CD31 vascu-
lar endothelial adhesion protein. CD31・positive
vessels significantly decreased by 






































































Fig. 4.E任ectof trientine on CD31・positivecel area index(A)， apoptosis index (B) and PCNA-positive cells 
index(C) in animals with BNL-HCC加mors，resp巴ctively.For each of the tumors. * p<O.OI compared wi白
血econtrol group. 


































Fig. 5.Effect of trientine on出ein vitro proliferation of HCC tumor αlls(A) and endothelial cels侶).Cell prolif-
eration was measured by MTT as羽 yat 24， 48， 72 and 96hr. Trientine was added to the medium at 1.0μ 
g/ml. Each point repr回 entsthe m位 nI SD(n=6). * pく0.01compared with出巴controlgroup. 
















Fig. 6. Representative photomicrographs of a GST.P.positive preneoplastic lesion in 
the liver. No bistological changes indica出 gliver injury or liver fibrosis were 
observed except for the development of GST.P.positive preneoplastic lesions. 
M砲 nifi臼 tionx 100. 
Tabl巴1.Effect of仕ientineon the development of GST-P-positive lesions and Cu con・
tcnt in the liver 
GST・Ppositive lesions 
Cu(μg/ 
No. (lcm2) Size (mm2/] (2) 
liver weight) 
DEN 31.36+4.16 5.53+0.53 86+6.8 
DEN + Tri ( 750) 22.40+3.20* 2.93+0.80“ 42+4.8本*
DEN + Tri (3000) 21.12+3.84* 2.67+0.47** 39+5.1 ** 
DEN +TJ-9 15.36+4.80*滋 2.87+1.00** 82+6.6 
PBS N.D. N.D. 85+6.9 
* : p<O.05 VS. DEN trea阻 entgroup. 料 :p<O.Ol VS. DEN佐官atmentgroup.
(244) 乞k口 井 純
Table 1. Effect of trientine on CD31 mRNA加 dPCNA-positive cells in出巴 DEN-tr巴atedliver 
CD31 mRNA expression PCNA positve 
(/ GAPDH) cels (%) 
DEN 2.52+0.42 4.41+1.24 
車*
DEN + Tri ( 750) 1.58+0.26 4.35+1.18 
車*
DEN + Tri (3000) 1.55+0.23 4.47+1.18 





















































































した.さらに， トリエンチンを投与した実験動物におい を考えあわせると， トリエンチンは血管新生を阻害して
て，対照群に比し，体重減少やトランスアミナーゼの有 前癌病変がある大きさ以上になることを主に抑制してい
意な変化といったいかなる毒性も認められなかった.現 る可能性が大きいと考えられた.
段階ではこれら 2薬物で抗臆蕩効果に差異が生じた理由 本実験で用いた 750ppmというトリエンチン漉度は、
は明らかではない.2薬物ともに銅のみをキレートし， 1日あたり 97.5mg/kgの投与量に相当する.臨床におけ
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